AtriCure

ATRC · NASDAQ

$57.67+$2.14 (+3.85%)TodayMarket closed ·
Prev close $55.53

About ATRC

AtriCure, Inc. engages in the development, manufacture, and sale of surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. The company is headquartered in Mason, Ohio and currently employs 1,350 full-time employees. The company went IPO on 2005-08-05. The firm's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The firm's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.

Employees
1,350
Headquarters
Mason, Ohio
Listed
Aug 5, 2005
Sector
Health Care
Industry
Health Care Equipment & Supplies

Leadership

AtriCure executives
NameTitleSince
Robert White——
Michael Carrel—2012
Angela Wirick——
Douglas Seith——
Salvatore Privitera——
Justin Noznesky——
Vinayak Doraiswamy——
Karl Dahlquist——
Regina Groves——
B. Kristine Johnson——
Shlomo Nachman——
Karen Prange——
Deborah Telman——
Sven Wehrwein——
Maggie Yuen——

Revenue by product and region

Fiscal year ended Dec 31, 2025: $534.53M total revenue

By region

  • United States$435.37M81.4%
  • Europe$61.49M11.5%

Similar companies

Companies in the same industry as AtriCure

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.